Symbols / RNXT Stock $0.87 -10.60% RenovoRx, Inc.

Healthcare • Biotechnology • United States • NCM
RNXT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Shaun R. Bagai
Exch · Country NCM · United States
Market Cap 39.33M
Enterprise Value 31.71M
Income -12.27M
Sales 1.49M
FCF (ttm) -6.38M
Book/sh 0.25
Cash/sh 0.27
Employees 17
Insider 10d —
IPO Aug 26, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.81
PEG —
P/S 26.41
P/B 3.49
P/C —
EV/EBITDA -2.56
EV/Sales 21.29
Quick Ratio 6.58
Current Ratio 7.15
Debt/Eq 0.69
LT Debt/Eq —
EPS (ttm) -0.33
EPS next Y -0.15
EPS Growth —
Revenue Growth 185.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-05-14
ROA -51.58%
ROE -100.48%
ROIC —
Gross Margin 78.71%
Oper. Margin -6.16%
Profit Margin 0.00%
Shs Outstand 45.10M
Shs Float 39.90M
Insider Own 3.77%
Instit Own 19.01%
Short Float 0.88%
Short Ratio 1.34
Short Interest 384.04K
52W High 1.45
vs 52W High -39.86%
52W Low 0.70
vs 52W Low 24.39%
Beta —
Impl. Vol. —
Rel Volume 0.86
Avg Volume 377.06K
Volume 325.90K
Target (mean) $7.03
Tgt Median $5.56
Tgt Low $3.00
Tgt High $14.00
# Analysts 4
Recom Strong_buy
Prev Close $0.98
Price $0.87
Change -10.60%
About

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.03
Mean price target
2. Current target
$0.87
Latest analyst target
3. DCF / Fair value
$-2.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.87
Low
$3.00
High
$14.00
Mean
$7.03

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-01 main Ascendiant Capital Buy → Buy $14
2026-04-09 main Ascendiant Capital Buy → Buy $14
2026-04-08 reit HC Wainwright & Co. Buy → Buy $3
2026-02-17 main Ascendiant Capital Buy → Buy $13
2025-11-21 main Ascendiant Capital Buy → Buy $13
2025-08-25 main Ascendiant Capital Buy → Buy $12
2025-06-05 main Ascendiant Capital Buy → Buy $12
2025-05-19 reit HC Wainwright & Co. Buy → Buy $3
2025-04-28 main Ascendiant Capital Buy → Buy $11
2025-04-04 reit HC Wainwright & Co. Buy → Buy $3
2025-03-27 init HC Wainwright & Co. — → Buy $3
2024-12-10 main Ascendiant Capital Buy → Buy $9
2024-09-12 main Ascendiant Capital Buy → Buy $8
2024-06-17 init Ascendiant Capital — → Buy $8
2024-02-02 init Alliance Global Partners — → Buy $4
2023-11-15 down Maxim Group Buy → Hold —
2023-08-18 main Roth MKM Buy → Buy $13
2021-11-01 init Roth Capital — → Buy $16
2021-10-06 init Maxim Group — → Buy $15
News
RSS: Latest RNXT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-19 VOLL MARK Chief Financial Officer — 25,000 $0.79 $19,690
2026-04-02 VOLL MARK Chief Financial Officer — 80,000 $0.00 $0
2026-03-25 VOLL MARK Chief Financial Officer — 12,380 $0.00 $0
2026-03-20 VOLL MARK Chief Financial Officer — 97,200 $1.00 $97,200
2026-03-20 MARTON LAURENCE Director — 9,720 $1.00 $9,720
2026-03-20 BAGAI SHAUN R. Chief Executive Officer — 24,300 $1.00 $24,300
2026-01-21 AGAH RAMTIN M.D. Officer and Director — 10,000 $1.00 $9,975
2025-12-31 AGAH RAMTIN M.D. Officer and Director — 9,795 $0.86 $8,424
2025-12-30 AGAH RAMTIN M.D. Officer and Director — 205 $0.83 $169
2025-12-18 BAGAI SHAUN R. Chief Executive Officer — 5,000 $0.90 $4,506
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.12
+2511.63%
0.04
0.00
0.00
Operating Revenue
1.12
+2511.63%
0.04
0.00
0.00
Cost Of Revenue
0.33
0.00
0.00
—
Reconciled Cost Of Revenue
0.33
0.00
0.00
—
Gross Profit
0.80
+1751.16%
0.04
0.00
—
Operating Expense
13.31
+20.83%
11.01
-3.36%
11.40
+14.53%
9.95
Research And Development
6.27
+4.05%
6.03
+6.32%
5.67
+31.76%
4.30
Selling General And Administration
7.04
+41.10%
4.99
-12.93%
5.73
+1.42%
5.65
General And Administrative Expense
7.04
+41.10%
4.99
-12.93%
5.73
+1.42%
5.65
Salaries And Wages
3.27
+21.52%
2.69
+9.04%
2.47
+28.81%
1.92
Other Gand A
3.77
+64.04%
2.30
-29.56%
3.26
-12.64%
3.73
Total Expenses
13.63
+23.80%
11.01
-3.36%
11.40
+14.53%
9.95
Operating Income
-12.51
-14.05%
-10.97
+3.74%
-11.40
-14.53%
-9.95
Total Operating Income As Reported
-12.51
-14.04%
-10.97
+3.74%
-11.40
-14.53%
-9.95
EBITDA
-12.51
-14.03%
-10.97
+3.74%
-11.40
-14.60%
-9.94
Normalized EBITDA
-13.42
-5.35%
-12.74
+2.77%
-13.11
-31.79%
-9.94
Reconciled Depreciation
0.00
0.00
0.00
-100.00%
0.01
EBIT
-12.51
-14.05%
-10.97
+3.74%
-11.40
-14.53%
-9.95
Total Unusual Items
0.92
-48.36%
1.77
+3.69%
1.71
0.00
Total Unusual Items Excluding Goodwill
0.92
-48.36%
1.77
+3.69%
1.71
0.00
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Net Income
-11.17
-26.71%
-8.81
+13.86%
-10.23
-3.47%
-9.89
Pretax Income
-11.17
-26.72%
-8.81
+13.86%
-10.23
-3.47%
-9.89
Net Non Operating Interest Income Expense
0.43
+11.20%
0.38
+170.46%
-0.55
-1056.14%
0.06
Interest Expense Non Operating
—
—
—
—
Net Interest Income
0.43
+11.20%
0.38
+170.46%
-0.55
-1056.14%
0.06
Interest Expense
—
—
—
—
Interest Income Non Operating
0.43
+11.20%
0.38
—
0.06
Interest Income
0.43
+11.20%
0.38
—
0.06
Other Income Expense
0.92
-48.36%
1.77
+3.69%
1.71
+42625.00%
0.00
Other Non Operating Income Expenses
—
—
—
0.00
Gain On Sale Of Security
0.92
-48.36%
1.77
+3.69%
1.71
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-11.17
-26.72%
-8.81
+13.86%
-10.23
-3.47%
-9.89
Net Income From Continuing Operation Net Minority Interest
-11.17
-26.71%
-8.81
+13.86%
-10.23
-3.47%
-9.89
Net Income From Continuing And Discontinued Operation
-11.17
-26.71%
-8.81
+13.86%
-10.23
-3.47%
-9.89
Net Income Continuous Operations
-11.17
-26.72%
-8.81
+13.86%
-10.23
-3.47%
-9.89
Normalized Income
-12.08
-14.14%
-10.59
+11.35%
-11.94
-20.75%
-9.89
Net Income Common Stockholders
-11.17
-26.71%
-8.81
+13.86%
-10.23
-3.47%
-9.89
Diluted EPS
-0.32
+20.00%
-0.40
+59.60%
-0.99
+9.17%
-1.09
Basic EPS
-0.32
+20.00%
-0.40
+59.60%
-0.99
+9.17%
-1.09
Basic Average Shares
35.33
+58.65%
22.27
+116.42%
10.29
+13.69%
9.05
Diluted Average Shares
35.33
+58.65%
22.27
+116.42%
10.29
+13.69%
9.05
Diluted NI Availto Com Stockholders
-11.17
-26.71%
-8.81
+13.86%
-10.23
-3.47%
-9.89
Total Other Finance Cost
—
-0.38
-170.46%
0.55
+1056.14%
-0.06
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
8.10
-0.28%
8.12
+453.75%
1.47
-79.82%
7.26
Current Assets
7.89
+0.83%
7.83
+433.97%
1.47
-79.82%
7.26
Cash Cash Equivalents And Short Term Investments
7.02
-1.82%
7.15
+509.89%
1.17
-81.79%
6.44
Cash And Cash Equivalents
7.02
-1.82%
7.15
+509.89%
1.17
-73.29%
4.39
Other Short Term Investments
—
—
0.00
-100.00%
2.05
Receivables
0.14
+223.26%
0.04
0.00
—
Accounts Receivable
0.14
+223.26%
0.04
0.00
—
Inventory
0.19
0.00
—
—
Finished Goods
0.19
0.00
—
—
Prepaid Assets
0.32
-1.22%
0.33
+95.24%
0.17
—
Current Deferred Assets
—
0.00
-100.00%
0.10
0.00
Other Current Assets
0.22
-28.38%
0.30
+1162.50%
0.02
-97.09%
0.82
Total Non Current Assets
0.20
-30.34%
0.29
0.00
0.00
Net PPE
0.20
-30.34%
0.29
0.00
0.00
Gross PPE
0.20
-29.66%
0.29
0.00
0.00
Accumulated Depreciation
-0.00
0.00
0.00
—
Properties
—
—
—
0.00
Machinery Furniture Equipment
0.01
+16.67%
0.01
0.00
—
Other Properties
0.19
-31.65%
0.28
—
—
Leases
—
—
—
0.00
Non Current Prepaid Assets
—
—
—
—
Total Liabilities Net Minority Interest
2.67
-26.57%
3.64
-18.50%
4.47
+305.26%
1.10
Current Liabilities
1.96
+2.78%
1.91
+62.47%
1.18
+6.62%
1.10
Payables And Accrued Expenses
1.11
+8.09%
1.03
-6.73%
1.10
+75.44%
0.63
Payables
0.80
+36.35%
0.59
+4.46%
0.56
+5.06%
0.53
Accounts Payable
0.80
+36.35%
0.59
+4.46%
0.56
+5.06%
0.53
Current Accrued Expenses
0.31
-29.55%
0.44
-18.37%
0.54
+479.57%
0.09
Pensionand Other Post Retirement Benefit Plans Current
0.75
-8.45%
0.82
+989.33%
0.07
-84.21%
0.47
Current Debt And Capital Lease Obligation
0.10
+59.09%
0.07
—
—
Current Capital Lease Obligation
0.10
+59.09%
0.07
0.00
—
Total Non Current Liabilities Net Minority Interest
0.71
-58.93%
1.73
-47.40%
3.29
0.00
Long Term Debt And Capital Lease Obligation
0.11
-49.53%
0.21
0.00
—
Long Term Capital Lease Obligation
0.11
-49.53%
0.21
0.00
—
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
5.42
+21.08%
4.48
+249.27%
-3.00
-148.68%
6.16
Common Stock Equity
5.42
+21.08%
4.48
+249.27%
-3.00
-148.68%
6.16
Capital Stock
0.00
+100.00%
0.00
+100.00%
0.00
+0.00%
0.00
Common Stock
0.00
+100.00%
0.00
+100.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
36.61
+52.34%
24.03
+124.76%
10.69
+17.54%
9.10
Ordinary Shares Number
36.61
+52.34%
24.03
+124.76%
10.69
+17.54%
9.10
Additional Paid In Capital
66.81
+22.14%
54.70
+42.42%
38.40
+2.91%
37.32
Retained Earnings
-61.39
-22.24%
-50.22
-21.29%
-41.41
-32.82%
-31.17
Gains Losses Not Affecting Retained Earnings
—
0.00
0.00
-100.00%
0.02
Other Equity Adjustments
—
—
—
0.02
Total Equity Gross Minority Interest
5.42
+21.08%
4.48
+249.27%
-3.00
-148.68%
6.16
Total Capitalization
5.42
+21.08%
4.48
+249.27%
-3.00
-148.68%
6.16
Working Capital
5.93
+0.20%
5.92
+1934.02%
0.29
-95.28%
6.16
Invested Capital
5.42
+21.08%
4.48
+249.27%
-3.00
-148.68%
6.16
Total Debt
0.21
-23.74%
0.28
0.00
—
Capital Lease Obligations
0.21
-23.74%
0.28
0.00
—
Net Tangible Assets
5.42
+21.08%
4.48
+249.27%
-3.00
-148.68%
6.16
Tangible Book Value
5.42
+21.08%
4.48
+249.27%
-3.00
-148.68%
6.16
Derivative Product Liabilities
0.60
-60.24%
1.52
-53.84%
3.29
0.00
Interest Payable
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.97
-20.25%
-9.12
+11.05%
-10.26
-16.42%
-8.81
Cash Flow From Continuing Operating Activities
-10.97
-20.25%
-9.12
+11.05%
-10.26
-16.42%
-8.81
Net Income From Continuing Operations
-11.17
-26.71%
-8.81
+13.86%
-10.23
-3.47%
-9.89
Depreciation Amortization Depletion
0.00
0.00
0.00
-100.00%
0.01
Depreciation
0.00
0.00
0.00
-100.00%
0.01
Depreciation And Amortization
0.00
0.00
0.00
-100.00%
0.01
Other Non Cash Items
0.09
+1157.14%
0.01
—
—
Stock Based Compensation
1.27
+7.92%
1.17
+8.91%
1.08
+67.39%
0.64
Operating Gains Losses
-0.92
+48.36%
-1.77
-3.69%
-1.71
—
Gain Loss On Investment Securities
-0.92
+48.36%
-1.77
-3.69%
-1.71
—
Change In Working Capital
-0.25
-188.21%
0.28
-53.72%
0.60
+41.36%
0.43
Change In Receivables
-0.10
0.00
—
—
Changes In Account Receivables
-0.10
0.00
—
—
Change In Inventory
-0.19
0.00
—
—
Change In Prepaid Assets
0.09
+156.25%
-0.16
-125.28%
0.63
+139.77%
0.26
Change In Payables And Accrued Expense
-0.05
-107.87%
0.66
+805.48%
0.07
-52.90%
0.15
Change In Accrued Expense
-0.27
-141.67%
0.64
+1282.61%
0.05
-70.32%
0.15
Change In Payable
0.21
+752.00%
0.03
-7.41%
0.03
+200.00%
0.01
Change In Account Payable
0.21
+752.00%
0.03
-7.41%
0.03
0.00
Change In Other Current Assets
0.00
+100.00%
-0.22
-118.81%
-0.10
-1222.22%
0.01
Investing Cash Flow
-0.00
+83.33%
-0.01
-100.59%
2.03
+200.00%
-2.03
Cash Flow From Continuing Investing Activities
-0.00
+83.33%
-0.01
-100.59%
2.03
+200.00%
-2.03
Net PPE Purchase And Sale
-0.00
+83.33%
-0.01
0.00
—
Purchase Of PPE
-0.00
+83.33%
-0.01
0.00
—
Capital Expenditure
-0.00
+83.33%
-0.01
—
—
Capital Expenditure Reported
—
—
—
0.00
Net Investment Purchase And Sale
—
0.00
-100.00%
2.03
+200.00%
-2.03
Purchase Of Investment
—
—
0.00
+100.00%
-8.00
Sale Of Investment
—
0.00
-100.00%
2.03
-65.95%
5.97
Financing Cash Flow
10.85
-28.26%
15.12
+201.88%
5.01
+11823.81%
0.04
Cash Flow From Continuing Financing Activities
10.85
-28.26%
15.12
+201.88%
5.01
+11823.81%
0.04
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
12.10
-29.84%
17.25
+244.96%
5.00
0.00
Proceeds From Stock Option Exercised
0.04
-58.82%
0.10
+1175.00%
0.01
-80.95%
0.04
Net Other Financing Charges
-1.30
+41.80%
-2.23
—
—
Changes In Cash
-0.13
-102.17%
5.98
+285.86%
-3.22
+70.21%
-10.80
Beginning Cash Position
7.15
+509.89%
1.17
-73.29%
4.39
-71.10%
15.19
End Cash Position
7.02
-1.82%
7.15
+509.89%
1.17
-73.29%
4.39
Free Cash Flow
-10.97
-20.12%
-9.14
+10.93%
-10.26
-16.42%
-8.81
Interest Paid Supplemental Data
0.02
-23.81%
0.02
+50.00%
0.01
—
Income Tax Paid Supplemental Data
0.00
-50.00%
0.00
-94.74%
0.04
—
Change In Interest Payable
—
—
—
—
Common Stock Issuance
12.10
-29.84%
17.25
+244.96%
5.00
0.00
Issuance Of Capital Stock
12.10
-29.84%
17.25
+244.96%
5.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category